Belite Bio's tinlarebant gets FDA priority review for Stargardt disease
Belite Bio announced on 11 August 2026 that the US Food and Drug Administration has accepted its New Drug Application for tinlarebant and granted it Priority Review for the treatment of Stargardt disease Type 1, the most common form of inherited juvenile macular degeneration.
Tinlarebant is a novel once-daily oral therapy that reduces the accumulation of vitamin A-based toxins (bisretinoids) that drive retinal degeneration in Stargardt disease and also contribute to geographic atrophy in advanced dry age-related macular degeneration. It works by lowering serum retinol binding protein 4 (RBP4) — the sole carrier protein delivering retinol to the eye — thereby curbing bisretinoid formation.
The candidate carries an unusually broad regulatory footprint: Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations in the US, Orphan Drug designation in the US, Europe, Japan and Switzerland, and Sakigake designation in Japan. Priority Review shortens the FDA's target action timeline, moving the clinical-stage biotech a step closer to a first approval.